Therapy Areas: AIDS & HIV
Gilead expands global access to lenacapavir for HIV prevention
2 October 2024 - HIV medication company Gilead Sciences Inc (Nasdaq: GILD) announced on Wednesday that it has signed royalty-free voluntary licensing agreements with six generic manufacturers to incre...
Alume Biosciences names new chief commercial officer
16 September 2024 - California-based late-stage biotech company Alume Biosciences announced on Friday that it has named Rick Gonzalez as its new chief commercial officer.Gonzalez has more than three d...
genedrive plc secures initial UK order for Genedrive CYP2C19-ID Kit
12 August 2024 - Point-of-care pharmacogenetic testing company genedrive plc (AIM: GDR) announced on Monday that it has made its first UK commercial sale of the Genedrive CYP2C19-ID Kit.This follows g...
Gilead's lenacapavir demonstrates 100% efficacy in HIV prevention trial
24 July 2024 - HIV research company Gilead Sciences Inc (Nasdaq: GILD) on Wednesday presented full efficacy and safety results from its Phase 3 PURPOSE 1 trial at the 25th International AIDS Conferenc...
Gilead study suggests lenacapavir superior to Truvada
20 June 2024 - Biopharmaceutical company Gilead Sciences Inc (Nasdaq:GILD) on Thursday released topline results from an interim analysis of a Phase 3 trial indicating that the company's twice-yea...
Oxford BioDynamics announces opening of clinical testing facility in UK for prostate screening test
3 April 2024 - Biotechnology company Oxford BioDynamics, Plc (AIM: OBD) announced on Wednesday that clinical validation of its EpiSwitch Prostate Screening (PSE) test has been completed at its newly c...